Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 22, 2022 - Issue 11
Submit an article Journal homepage
1,609
Views
1
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan

Kentaro Haradaa Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan;b Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanView further author information
,
Shun Yamamotoa Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, JapanView further author information
&
Ken Katoa Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1733-5072View further author information
ORCID Icon
Pages 1333-1338 | Received 25 Jun 2022, Accepted 17 Oct 2022, Published online: 20 Oct 2022

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.